Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TXNRD1 | Q16881 | 3/20 | 0.34 |
| ▸ | TXNRD3 | Q86VQ6 | 3/20 | 0.34 |
| ▸ | TXNRD2 | Q9NNW7 | 3/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19679616 | 0.81 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL19677583 | 0.81 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL15144336 | 0.76 | ALDH1A1 (0.67) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL16806476 | 0.76 | ALDH1A1 (0.67) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL17831052 | 0.76 | ALDH1A1 (0.67) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL25029916 | 0.76 | ALDH1A1 (0.67) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL23384635 | 0.76 | ALDH1A1 (0.67) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL12450530 | 0.74 | ALDH1A1 (0.56) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL21371726 | 0.74 | ALDH1A1 (0.56) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL25726864 | 0.74 | ALDH1A1 (0.56) | ALDH1A1TSHRLMNATDP1TXNRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348425-A1 | NON-CLEAVABLE POLYMER CONJUGATED WITH ALPHA V BETA 3 INTEGRIN THYROID ANTAGONISTS | NANOPHARMACEUTICALS, LLC | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348425-A1 | NON-CLEAVABLE POLYMER CONJUGATED WITH ALPHA V BETA 3 INTEGRIN THYROID ANTAGONISTS | THRA, CD44, ITGAV | ALDH1A1 1334/4885TSHR 6/4885LMNA 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.